Tert-butyl 4-[3-[[2-(3-ethyl-2-oxobenzimidazol-1-yl)-1,3-thiazole-4-carbonyl]amino]pyridin-4-yl]piperazine-1-carboxylate | 1023298-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Tert-butyl 4-[3-[[2-(3-ethyl-2-oxobenzimidazol-1-yl)-1,3-thiazole-4-carbonyl]amino]pyridin-4-yl]piperazine-1-carboxylate
• CAS: 1023298-75-0
• 化学式: C₂₇H₃₁N₇O₄S
• 分子量: 549.654
• InChiKey: KNMLXGMVDAHKCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  139
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-乙基-2-苯并咪唑酮 、 tert-butyl 4-(3-(2-bromothiazole-4-carboxamido)pyridin-4-yl)piperazine-1-carboxylate 在 copper(l) iodide potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以61%的产率得到Tert-butyl 4-[3-[[2-(3-ethyl-2-oxobenzimidazol-1-yl)-1,3-thiazole-4-carbonyl]amino]pyridin-4-yl]piperazine-1-carboxylate
  参考文献：
  名称：

  WO2008/54749

  摘要：

  公开号：

文献信息

• 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS
  申请人：Shipps, JR. Gerald W.

  公开号：US20100130465A1

  公开（公告）日：2010-05-27

  The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.

  本发明涉及一种新型的Anilinopiperazine衍生物的公式(I)，包括该Anilinopiperazine衍生物的组合物，并且使用该Anilinopiperazine衍生物治疗或预防增生性疾病、抗增生性疾病、炎症、关节炎、中枢神经系统疾病、心血管疾病、脱发、神经疾病、缺血性损伤、病毒性疾病、真菌感染或与蛋白激酶活性相关的疾病的方法。
• ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT
  申请人：Basso-Porcaro Andrea Dawn

  公开号：US20100249030A1

  公开（公告）日：2010-09-30

  The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.

  本发明涉及一种通过预先使用抗有丝分裂剂，然后再使用至少一种极化素激酶抑制剂来治疗癌症的方法。详细说明了在本发明治疗中有用的抗有丝分裂剂和极化素激酶抑制剂。
• US8318735B2
  申请人：——

  公开号：US8318735B2

  公开（公告）日：2012-11-27
• [EN] 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS<br/>[FR] AMIDES 2-AMINOTHIAZOLE-4-CARBOXYLIQUES UTILISÉS COMME INHIBITEURS DE PROTÉINES KINASES
  申请人：SCHERING CORP

  公开号：WO2008054749A1

  公开（公告）日：2008-05-08

  [EN] The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.
  [FR] La présente invention concerne de nouveaux dérivés d'anilinopipérazine de formule (I), des compositions comprenant ces dérivés d'anilinopipérazine ainsi que des méthodes d'utilisation de ces dérivés d'anilinopipérazine pour traiter ou prévenir un trouble prolifératif, un trouble anti-prolifératif, l'inflammation, l'arthrite, un trouble du système nerveux central, une maladie cardiovasculaire, l'alopécie, une maladie neuronale, une lésion ischémique, une maladie virale, une infection fongique ou un trouble associé à l'activité d'une protéine kinase.
• [EN] ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT<br/>[FR] COMBINAISON D'AGENT ANTIMITOTIQUE ET D'INHIBITEUR DE L'AURORA KINASE COMME TRAITEMENT ANTI-CANCER
  申请人：SCHERING CORP

  公开号：WO2009017701A2

  公开（公告）日：2009-02-05

  The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.